Safe and Effective Management of Dry Eye Symptoms with Hydroxypropyl Guar and Hyaluronic Acid Dual-Polymer Lubricating Eye Drops: A Review of Preclinical and Clinical Studies

References

• Pflugfelder SC, de Paiva CS. The Pathophysiology of Dry Eye Disease: what We Know and Future Directions for Research. Ophthalmology. 2017;124(11):S4–S13. doi:10.1016/j.ophtha.2017.07.010
   PubMed Web of Science ®Google Scholar
• Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3):334–365. doi:10.1016/j.jtos.2017.05.003
   PubMed Web of Science ®Google Scholar
• Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf. 2017;15(3):539–574. doi:10.1016/j.jtos.2017.05.001
   PubMed Web of Science ®Google Scholar
• Barabino S, Benitez-Del-Castillo JM, Fuchsluger T, et al. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification. Eur Rev Med Pharmacol Sci. 2020;24(17):8642–8652. doi:10.26355/eurrev_202009_22801
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008
   PubMed Web of Science ®Google Scholar
• Lemp MA, Baudouin C, Baum J, et al. The definition and classification of dry eye disease: report of the definition and classification subcommittee of the international Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75–92. doi:10.1016/s1542-0124(12)70081-2
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf. 2017;15(3):575–628. doi:10.1016/j.jtos.2017.05.006
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017;15(4):802–812. doi:10.1016/j.jtos.2017.08.003
   PubMed Web of Science ®Google Scholar
• Módis L, Szalai E. Dry eye diagnosis and management. Expert Rev Ophthalmol. 2011;6(1):67–79. doi:10.1586/eop.10.89
   Google Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016;2016(2). doi:10.1002/14651858.CD009729.pub2
   Web of Science ®Google Scholar
• Labetoulle M, Benitez-Del-castillo JM, Barabino S, et al. Artificial Tears: biological Role of Their Ingredients in the Management of Dry Eye Disease. Int J Mol Sci. 2022;23(5). doi:10.3390/ijms23052434
   PubMed Web of Science ®Google Scholar
• Agarwal P, Craig JP, Rupenthal ID. Formulation considerations for the management of dry eye disease. Pharmaceutics. 2021;13(2):1–19. doi:10.3390/pharmaceutics13020207
   Web of Science ®Google Scholar
• Labetoulle M, Messmer EM, Pisella PJ, Ogundele A, Baudouin C. Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye. Br J Ophthalmol. 2017;101(4):487–492. doi:10.1136/bjophthalmol-2016-308608
   PubMed Web of Science ®Google Scholar
• Labetoulle M, Schmickler S, Galarreta D, et al. Efficacy and safety of dual-polymer hydroxypropyl guar-and hyaluronic acid-containing lubricant eyedrops for the management of dry-eye disease: a randomized double-masked clinical study. Clin Ophthalmol. 2018;12:2499–2508. doi:10.2147/OPTH.S177176
   PubMed Web of Science ®Google Scholar
• Moon SW, Hwang JH, Chung SH, Nam KH. The impact of artificial tears containing hydroxypropyl guar on mucous layer. Cornea. 2010;29(12):1430–1435. doi:10.1097/ICO.0b013e3181ca636b
   PubMed Web of Science ®Google Scholar
• Posarelli C, Passani A, Del Re M, et al. Cross-Linked Hyaluronic Acid as Tear Film Substitute. J Ocul Pharmacol Ther. 2019;35(7):381–387. doi:10.1089/jop.2018.0151
   PubMed Web of Science ®Google Scholar
• Schmidl D, Schmetterer L, Witkowska KJ. Tear Film Thickness After Treatment With Artificial Tears in Patients With Moderate Dry Eye Disease. Cornea. 2015;34(4):421–426. doi:10.1097/ICO.0000000000000358
   PubMed Web of Science ®Google Scholar
• Park Y, Song JS, Choi CY, Yoon KC, Lee HK, Kim HS. A Randomized Multicenter Study Comparing 0.1%, 0.15%, and 0.3% Sodium Hyaluronate with 0.05% Cyclosporine in the Treatment of Dry Eye. J Ocul Pharmacol Ther. 2017;33(2):66–72. doi:10.1089/jop.2016.0086
   PubMed Web of Science ®Google Scholar
• Systane Hydration drug facts. Available from: https://fda.report/DailyMed/8936f66f-10fe-44ab-a26e-dd8b05dfa997. Accessed January 11, 2023.
   Google Scholar
• Jones L, Ngo W, Yeh T SYSTANE ® HYDRATION PF’s Dual-Polymer Technology: hydroxypropyl-Guar and Sodium Hyaluronate [White Paper]. Available from: Https://Us.Alconscience.Com/Sites/g/Files/Rbvwei1736/Files/Pdf/SYSTANE-HYDRATION-PFs-Dua. Accessed January 11, 2023.
   Google Scholar
• Aragona P, Simmons PA, Wang H, Wang T. Physicochemical Properties of Hyaluronic Acid-Based Lubricant Eye Drops. Transl Vis Sci Technol. 2019;8(6):2. doi:10.1167/tvst.8.6.2
   PubMed Web of Science ®Google Scholar
• Rangarajan R, Kraybill B, Ogundele A, Ketelson HA. Effects of a Hyaluronic Acid/Hydroxypropyl Guar Artificial Tear Solution on Protection, Recovery, and Lubricity in Models of Corneal Epithelium. J Ocul Pharmacol Ther. 2015;31(8):491–497. doi:10.1089/jop.2014.0164
   PubMed Web of Science ®Google Scholar
• Bitton E, Perugino C, Charette S. Comparison of Ocular Lubricant Osmolalities. Optom Vis Sci. 2017;94(6):694–699. doi:10.1097/OPX.0000000000001082
   PubMed Web of Science ®Google Scholar
• Springs CL. Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye. Adv Ther. 2010;27(10):681–690. doi:10.1007/s12325-010-0052-3
   PubMed Web of Science ®Google Scholar
• Benelli U. Systane® lubricant eye drops in the management of ocular dryness. Clin Ophthalmol. 2011;5(1):783–790. doi:10.2147/OPTH.S13773
   PubMedGoogle Scholar
• Garofalo R, Kunnen C, Rangarajan R, Manoj V, Ketelson H. Relieving the symptoms of dry eye disease: update on lubricating eye drops containing hydroxypropyl-guar. Clin Exp Optom. 2021;104(8):826–834. doi:10.1080/08164622.2021.1925208
   PubMed Web of Science ®Google Scholar
• Ng A, Keech A, Jones L. Tear osmolarity changes after use of hydroxypropyl-guar-based lubricating eye drops. Clin Ophthalmol. 2018;12:695–700. doi:10.2147/OPTH.S150587
   PubMed Web of Science ®Google Scholar
• Yeu E, Silverstein S, Guillon M, et al. Efficacy and safety of phospholipid nanoemulsion-based ocular lubricant for the management of various subtypes of dry eye disease: a Phase IV, multicenter trial. Clin Ophthalmol. 2020;14:2561–2570. doi:10.2147/OPTH.S261318
   PubMed Web of Science ®Google Scholar
• Davitt WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther. 2010;26(4):347–353. doi:10.1089/jop.2010.0025
   PubMed Web of Science ®Google Scholar
• Fernandez KB, Epstein SP, Raynor GS, et al. Modulation of HLA -DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution. Clin Ophthalmol. 2015;9:1137–1145. doi:10.2147/OPTH.S81355
   PubMed Web of Science ®Google Scholar
• Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7). doi:10.3390/polym10070701
   PubMed Web of Science ®Google Scholar
• Lõpez-García JS, García-Lozano I, Rivas L, Ramírez N, Raposo R, Méndez MT. Autologous serum eye drops diluted with sodium hyaluronate: clinical and experimental comparative study. Acta Ophthalmol. 2014;92(1). doi:10.1111/aos.12167
   PubMed Web of Science ®Google Scholar
• Hynnekleiv L, Magno M, Vernhardsdottir RR, et al. Hyaluronic acid in the treatment of dry eye disease. Acta Ophthalmol. 2022;100(8):844–860. doi:10.1111/aos.15159
   PubMed Web of Science ®Google Scholar
• Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry. 2011;82(1):38–43. doi:10.1016/j.optm.2010.08.003
   PubMedGoogle Scholar
• Szegedi S, Scheschy U, Schmidl D, et al. Effect of Single Instillation of Two Hyaluronic Acid-Based Topical Lubricants on Tear Film Thickness in Patients with Dry Eye Syndrome. J Ocul Pharmacol Ther. 2018;34(9):605–611. doi:10.1089/jop.2018.0069
   PubMed Web of Science ®Google Scholar
• Seino S, Matsuoka R, Masuda Y, Kunou M, Okada Y, Saika S. Topical hyaluronan alone promotes corneal epithelial cell migration whereas combination with benzalkonium chloride impairs epithelial wound healing. Cutan Ocul Toxicol. 2020;39(1):13–20. doi:10.1080/15569527.2019.1673402
   PubMed Web of Science ®Google Scholar
• Walsh K, Jones L. The use of preservatives in dry eye drops. Clin Ophthalmol. 2019;13:1409–1425. doi:10.2147/OPTH.S211611
   PubMed Web of Science ®Google Scholar
• Kim YH, Jung JC, Jung SY, Yu S, Lee KW, Park YJ. Comparison of the Efficacy of Fluorometholone With and Without Benzalkonium Chloride in Ocular Surface Disease. Cornea. 2015;35(2):234–242. doi:10.1097/ICO.0000000000000695
   Web of Science ®Google Scholar
• Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. Eye. 2022;36(2):361–368. doi:10.1038/s41433-021-01668-x
   PubMed Web of Science ®Google Scholar
• Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15(3):511–538. doi:10.1016/j.jtos.2017.05.004
   PubMed Web of Science ®Google Scholar
• Hsu KH, Gupta K, Nayaka H, Donthi A, Kaul S, Chauhan A. Multidose Preservative Free Eyedrops by Selective Removal of Benzalkonium Chloride from Ocular Formulations. Pharm Res. 2017;34(12):2862–2872. doi:10.1007/s11095-017-2270-8
   PubMed Web of Science ®Google Scholar
• Kaarniranta K, Ropo A. Preferences and ease of use of preservative-free IOP-lowering eye drop containers: a comparison of two multi-dose bottles. Clin Investig. 2018;07(04). doi:10.4172/clinical-investigation.1000126
   Google Scholar
• Davidson Z. Developing an efficient ophthalmic device combination product. ONdrugDelivery. 2020;2020(104):16–24.
   Google Scholar
• SAIDANE, LP.B. How to deliver preservative-free eye drops in a multidose system with a safer alternative to filters ? Invest Ophthalmol Vis Sci. 2017;58,4460.
   Web of Science ®Google Scholar
• Carlson E, Kao WWY, Ogundele A. Impact of Hyaluronic Acid-Containing Artificial Tear Products on Reepithelialization in an In Vivo Corneal Wound Model. J Ocul Pharmacol Ther. 2018;34(4):360–364. doi:10.1089/jop.2017.0080
   PubMed Web of Science ®Google Scholar
• Favuzza E, Cennamo M, Vicchio L, Giansanti F, Mencucci R. Protecting the Ocular Surface in Cataract Surgery: the Efficacy of the Perioperative Use of a Hydroxypropyl Guar and Hyaluronic Acid Ophthalmic Solution. Clin Ophthalmol. 2020;14:1769–1775. doi:10.2147/OPTH.S259704
   PubMed Web of Science ®Google Scholar
• Che Arif FA, Hilmi MR, Mohd Kamal K, Ithnin MH. Comparison of Immediate Effects on Usage of Dual Polymer Artificial Tears on Changes in Tear Film Characteristics. IIUM Med J Malaysia. 2020;18(3 SE). doi:10.31436/imjm.v18i2.613
   Google Scholar
• Tan J, Peguda R, Siddireddy JS, Briggs N, Stapleton F. Subjective Responses to Various Filling Solutions in the Posterior Fluid Reservoir of Miniscleral Lenses at Application. Eye Contact Lens. 2022;48(2):73–77. doi:10.1097/ICL.0000000000000855
   PubMed Web of Science ®Google Scholar
• Pastor-Pascual F, Pastor-Pascual R, Gálvez-Perez P, Dolz-Marco R, Gallego-Pinazo R. Use of Artificial Tears in Patients Undergoing Treatment with Anti-VEGF Intravitreal Injections. Clin Ophthalmol. 2022;16(November):3959–3972. doi:10.2147/OPTH.S391082
   PubMedGoogle Scholar
• Pucker AD, Lievens C, McGwin G, Franklin QX, Logan A, Wolfe GS. Quality of Life in Digital Device Users Who are Treated with Systane Hydration PF. Clin Optom. 2023;15(March):45–54. doi:10.2147/opto.s398496
   PubMedGoogle Scholar